Marshall Urist insider trades: Royalty Pharma (RPRX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Marshall reports to the SEC
Open-market buys and sales
20 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | RPRX | ↓ Sell | 4,126 | $57.10 | $236K | Direct | Oct 5, 2026 (0d) |
| Sep 28, 2026 | RPRX | ↓ Sell | 4,126 | $57.88 | $239K | Direct | Sep 30, 2026 (2d) |
| May 20, 2026 | RPRX | ↓ Sell | 13,684 | $52.75 | $722K | Direct | May 21, 2026 (1d) |
| May 14, 2026 | RPRX | ↓ Sell | 13,684 | $53.06 | $726K | Direct | May 15, 2026 (1d) |
| Jan 16, 2026 | RPRX | ↓ Sell | 20,000 | $39.52 | $790K | By Sandy Lamm LLC | Jan 20, 2026 (4d) |
| Jan 9, 2026 | RPRX | ↓ Sell | 20,000 | $40.78 | $816K | By Sandy Lamm LLC | Jan 13, 2026 (4d) |
| Jan 2, 2026 | RPRX | ↓ Sell10b5-1 | 20,000 | $38.48 | $770K | By Sandy Lamm LLC | Jan 6, 2026 (4d) |
| Dec 19, 2025 | RPRX | ↓ Sell | 20,000 | $38.38 | $768K | By Sandy Lamm LLC | Dec 22, 2025 (3d) |
| Dec 16, 2025 | RPRX | ↓ Sell | 20,000 | $38.32 | $766K | By Sandy Lamm LLC | Dec 17, 2025 (1d) |
| Dec 5, 2025 | RPRX | ↓ Sell | 23,334 | $39.15 | $914K | By Sandy Lamm LLC | Dec 9, 2025 (4d) |
| Dec 5, 2025 | RPRX | ↓ Sell | 18,242 | $39.15 | $714K | Direct | Dec 9, 2025 (4d) |
| Dec 1, 2025 | RPRX | ↓ Sell | 23,333 | $39.93 | $932K | By Sandy Lamm LLC | Dec 3, 2025 (2d) |
| Dec 1, 2025 | RPRX | ↓ Sell | 18,242 | $39.90 | $728K | Direct | Dec 3, 2025 (2d) |
| Feb 22, 2023 | RPRX | ↓ Sell | 23,333 | $37.30 | $870K | Direct | Feb 24, 2023 (2d) |
| Jul 26, 2022 | RPRX | ↓ Sell | 23,334 | $43.18 | $1.0M | Direct | Jul 27, 2022 (1d) |
| Jun 24, 2022 | RPRX | ↓ Sell | 23,333 | $43.19 | $1.0M | Direct | Jun 24, 2022 (0d) |
| May 16, 2022 | RPRX | ↓ Sell | 23,333 | $39.85 | $930K | Direct | May 16, 2022 (0d) |
| Jun 7, 2021 | RPRX | ↓ Sell | 33,134 | $46.08 | $1.5M | Direct | Jun 8, 2021 (1d) |
| Jun 2, 2021 | RPRX | ↓ Sell | 14,566 | $41.52 | $605K | Direct | Jun 4, 2021 (2d) |
| May 21, 2021 | RPRX | ↓ Sell | 2,000 | $41.08 | $82K | Direct | May 24, 2021 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RPRX insiders
Open-market trades in the last 12 months
About Marshall Urist's insider trades
Marshall Urist is EVP, Research & Investments at Royalty Pharma (RPRX). Since May 21, 2021, Marshall has reported no open-market purchases and 20 sales worth $15.1M on SEC Form 4. In the last 12 months: 13 sales ($9.1M).
1 sale (5% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (7 filings), conversions (5 filings), gifts (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RPRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.